Human Fibrinogen Pharma Grade API, designated under internal traceability code HFG-PG-01, is a plasma-derived, sterile-filterable lyophilized protein supplied for formulation into tablet, capsule, granule, and injectable presentations. The native molecule is a 340 kDa disulfide-bridged hexameric glycoprotein comprising two Aα, two Bβ, and two γ chains; thrombin cleaves fibrinopeptides A and B to generate fibrin monomer, which assembles into fibrin strands and is crosslinked by factor XIII. The injectable presentation is directed to restoration of hemostatic competence in congenital or acquired fibrinogen deficiency, whereas tablet, capsule, and granule presentations are intended for local oral, oromucosal, or gastrointestinal residence rather than systemic replacement. Intact fibrinogen is not absorbed across gastrointestinal epithelium, and systemic oral bioavailability is not an expected performance parameter; published data for pharmacologically relevant plasma levels after oral administration of intact fibrinogen is limited by enteral proteolysis and molecular size. Release specifications for the API are aligned to the European Pharmacopoeia monograph for human fibrinogen (Ph. Eur. 0024) and EU GMP Annex 14 for plasma-derived medicinal products, with donor-screening and viral safety requirements defined under ICH Q5A and current plasma master file guidance.

The API is distinguished from thrombin-based hemostatic agents by its role as a substrate rather than an enzyme and from animal-derived gelatin hemostats by direct participation in fibrin clot formation. It is also distinguished from crude cryoprecipitate by viral reduction capacity, control of total protein, and resolution of active fibrinogen mass per formulation unit. Bulk presentation is a lyophilized cake or powder requiring controlled reconstitution or solid-state processing; for tablet and capsule manufacturing, the active mass is calculated on clottable fibrinogen content rather than total protein mass.

What Specifications Define the Pharma-Grade API?

Because human fibrinogen is a complex plasma protein, the release matrix is dominated by functional clottability rather than chromatographic purity alone. Copurified proteins—including fibronectin, von Willebrand factor, and factor XIII—contribute to total protein without necessarily contributing to initial clot formation, so the ratio of clottable fibrinogen to total protein is a critical release attribute. Table 1 provides a representative release matrix; limits are batch-specific and must be reconciled with the approved marketing authorization variation and compendial monograph in force.

Viral risk is controlled by donor screening, inventory hold, and orthogonal reduction steps. Representative process-scale reduction includes solvent-detergent treatment with tri-n-butyl phosphate and polysorbate 80 at 30 °C for 4 h, nanofiltration through 20 nm membranes, and dry heat at 80 °C for 72 h as a final or intermediate step. These conditions are qualified against enveloped and non-enveloped model viruses; parvovirus B19 and hepatitis A require nanofiltration or heat because solvent-detergent alone is not effective against non-enveloped viruses. The API cannot be subjected to 121 °C steam terminal sterilization, making aseptic processing and process viral validation the two regulatory pillars for patient safety.

Lyophilization Heat Transfer and In-Vial Heterogeneity

Production-scale lyophilization introduces the first process boundary that controls downstream tableting and injectable reconstitution. In 10 m² stainless-steel freeze dryers, shelf ramp from -45 °C to +30 °C at chamber pressure of 0.2–0.4 mbar generates edge-vial temperatures 2–4 °C higher than center-vial temperatures during primary drying. This gradient becomes critical when product temperature approaches the collapse temperature, which for fibrinogen formulations can be depressed below -20 °C by sucrose or polysorbate-based stabilizers. Batch documentation from lyophilization lines records vial-to-vial moisture variance from 0.8% to 1.9% w/w when load configuration is uncontrolled. Cycles are therefore qualified at minimum and full load, and the API is sealed with desiccant in moisture-barrier foil or glass vials after unloading. Terminal steam sterilization is incompatible with this molecule: moist heat at 121 °C for 15 min produces insoluble aggregates and loss of clottable activity, so sterility is maintained by aseptic filtration through 0.22 µm PVDF membranes before lyophilization rather than by post-fill terminal treatment.

When the API is formulated into tablet, capsule, or granule presentations, the principal process risk shifts from sterility retention to shear-induced aggregation and moisture uptake at solid-dosage manufacturing interfaces. Direct compression on rotary tablet presses can generate local shear at die walls and punch faces; protein instability is typically observed when compression force exceeds 15–25 kN and the formulation lacks sufficiently plastic, low-melting-point diluents. High-shear wet granulation with impeller tip speeds above 5 m/s is generally avoided for this API because air-liquid interface stress and localized heating can denature fibrinogen. Published data for fibrinogen in high-shear granulators at production scale is limited; however, the molecular sensitivity of fibrinogen to interfacial stress supports roller compaction or low-shear tray drying as preferential processing routes. Excipients for solid oral presentations should be pre-dried to moisture below 2.0% w/w, and the processing environment is maintained below 35% relative humidity where feasible. Because intact fibrinogen is protease-labile, enteric-coated granules or protease-inhibitor-loaded capsule systems are limited to local enteric delivery concepts rather than systemic delivery objectives.

If Terminal Moisture Exceeds 3.0% w/w in Capsule Fill

Residual moisture above 3.0% w/w in a capsule fill containing lyophilized fibrinogen is a critical stability boundary, not a routine release target. At this moisture level, the amorphous protein matrix can undergo glass transition depression below 40 °C, permitting molecular mobility and aggregate formation during storage at 25 °C. Size-exclusion HPLC can track the high-molecular-weight species increase from below 2.0% to above 10.0% within 3 months under stressed conditions, depending on the stabilizer system. Moisture control must therefore be managed at the packaging level: desiccant selection in HDPE bottles should maintain headspace relative humidity below 20% at 25 °C and 60% ambient relative humidity, and gelatin capsule shells must be qualified for moisture transfer into the protein fill. If localized enteric residence is required, capsule or granule systems can be coated with methacrylic acid copolymers such as Eudragit L 100-55 or with HPMC phthalate; coating solvents and plasticizers must avoid ethanol-water mixtures that depress protein conformational stability and increase aggregation.

Where Oral and Injectable Grades Diverge in Excipient Selection

Injectable presentations require isotonizing and interface-stabilizing excipients that maintain rapid reconstitution without foam generation. Representative stabilizers include L-arginine hydrochloride, sodium citrate, human albumin, and polysorbate 80 at low concentration. Foam is not a cosmetic concern: air-liquid interfaces denature fibrinogen and reduce clottable activity during syringe transfer. Oral presentations, by contrast, do not require sterility, osmolality, or intravenous compatibility and can employ microcrystalline cellulose and mannitol as tablet diluents, provided these materials are controlled for peroxides and reducing sugars that could modify lysine or methionine residues. The acceptance boundary differs accordingly: injectable grade is controlled for sterility and endotoxin, while oral grade is controlled primarily for clottable activity, moisture stability, and absence of reducing sugar adducts after direct compression or granulation. Injectable-grade API meeting sterility and endotoxin limits can be used for solid oral development, but oral-grade API with lower bioburden control cannot be retrospectively upgraded to injectable status without repeating aseptic filtration, viral validation, and sterility release.

Comparative Performance Boundaries Against Thrombin, Recombinant Fibrinogen, and Gelatin Hemostats

Differences from other hemostatic products are defined by mechanism, source, stability, and formulation constraints. Unlike thrombin, fibrinogen is a substrate rather than an enzyme; it does not cleave other proteins, and it is not active until thrombin or an equivalent serine protease is present. Thrombin cannot be co-formulated with fibrinogen in a liquid state because immediate fibrin clot formation would occur. Recombinant fibrinogen avoids human plasma donation dependence and can have a narrower host-cell protein profile, but published production-scale stability data under solid oral processing is limited. Gelatin hemostats rely on physical tamponade and passive clot scaffolding rather than direct fibrin polymerization. Table 2 summarizes these boundaries.

Batch-scale experience in contract manufacturing of fibrinogen above 10 kg total protein has shown that filtration throughput is lower than for monoclonal antibodies at equivalent protein concentration. Reversible aggregate formation during 0.22 µm filtration is observed when protein concentration exceeds 20 mg/mL and process temperature exceeds 20 °C; filter capacity can decline by 30–50% at cold-room temperatures below 8 °C due to increased solution viscosity. This behavior supports dilution to 10–15 mg/mL and use of 0.45 µm prefilters before the sterilizing-grade membrane. Batch-to-batch variance in clottable fibrinogen ratio depends on plasma donor pool composition and cold precipitation conditions, so release testing reports active fibrinogen mass per gram of powder rather than total protein alone. Formulation calculations for tablet and capsule manufacture must use this active fibrinogen mass, because total protein content would overestimate the hemostatic dose when fibronectin, factor XIII, and other copurified proteins are present.